Obesity Medication Insurance Coverage? Employers Embrace the Inclusion of Novo Nordisk's Wegovy in Health Coverage
Portfolio Pulse from Vandana Singh
A survey by Accolade Inc and Savanta indicates that US employers are increasingly willing to include obesity medications like Novo Nordisk's Wegovy in their health coverage plans. The survey found that 43% of employers could potentially cover these drugs in 2024, up from the current 25%. Eli Lilly's Mounjaro, another GLP-1 diabetes drug, is also expected to gain approval for weight loss applications in the US this year. Aon Plc highlighted the economic implications of this trend, attributing a one percentage point rise in the anticipated 8.5% increase in employer healthcare costs to the uptick in employee utilization of weight-loss drugs.
October 10, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accolade Inc conducted a survey indicating increased employer willingness to cover obesity medications, potentially boosting its profile as a healthcare program provider.
The survey conducted by Accolade Inc could boost its profile as a healthcare program provider, potentially attracting more clients.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Aon Plc highlighted the economic implications of the increased employer coverage of obesity medications, potentially boosting its profile as a benefits consultant.
Aon's analysis of the economic implications of increased employer coverage of obesity medications could boost its profile as a benefits consultant.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Eli Lilly's Mounjaro is expected to gain approval for weight loss applications in the US this year, potentially boosting sales.
The expected approval of Mounjaro for weight loss applications could lead to increased sales for Eli Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Novo Nordisk's obesity medication Wegovy is expected to see increased coverage by US employers, potentially boosting sales.
The increased willingness of employers to cover obesity medications like Wegovy in their health plans could lead to increased sales for Novo Nordisk.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90